NGEN

MKT CAP:$315M

NervGen Pharma Corp. Common stock

Market Cap

$315M

Healthcare·Biotechnology·🇨🇦 Canada·NASDAQ

Healthcare·Biotechnology·🇨🇦·NASDAQ

Stock Price

$3.92-$1.96 (-33.33%)

Apr 24, 2026

Company Details

NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.

CEO

Adam H. Rogers

IPO Date

Feb 8, 2021

Website

www.nervgen.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$36M

EPS (Diluted)

-$0.49

Free Cash Flow

-$17M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$0.45

Q4 2025

Mar 31, 2026

$0EPS -$0.32

Q3 2025

Sep 29, 2025

$0EPS -$0.04

Q2 2025

Jun 29, 2025

$0EPS -$0.09

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$9.1K	-$4M
Q2 22	$0	-$26.6K	-$5M
Q3 22	$0	-$25.1K	-$4M
Q4 22	$0	-$25.6K	-$5M
Q1 23	$0	-$25.7K	-$3M
Q2 23	$0	-$26.4K	-$4M
Q3 23	$0	-$27.0K	-$3M
Q4 23	$0	-$29.1K	-$4M
Q1 24	$0	-$28.3K	-$4M
Q2 24	$0	-$11.0K	-$4M
Q3 24	$0	-$10.8K	-$5M
Q4 24	$0	-$11.0K	-$5M
Q1 25	$0	-$9.7K	-$4M
Q2 25	$0	-$10.2K	-$5M
Q3 25	$0	-$10.0K	-$4M
Q4 25	$0	$21.9K	-$9M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$3M	-$3M
Q2 22	-$3M	-$3M
Q3 22	-$3M	-$3M
Q4 22	-$4M	-$4M
Q1 23	-$4M	-$4M
Q2 23	-$2M	-$2M
Q3 23	-$1M	-$1M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$3M	-$3M
Q3 24	-$4M	-$4M
Q4 24	-$3M	-$3M
Q1 25	-$3M	-$3M
Q2 25	-$3M	-$3M
Q3 25	-$4M	-$4M
Q4 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$4.3K
Q2 22	$7.8K
Q3 22	$4.1K
Q4 22	$0
Q1 23	$0
Q2 23	$2.2K
Q3 23	$2.0K
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+125.4%
Q2 22	—	+119.3%
Q3 22	—	+23.1%
Q4 22	—	+52.7%
Q1 23	—	-12.8%
Q2 23	—	-26.6%
Q3 23	—	-29.3%
Q4 23	—	-26.5%
Q1 24	—	+5.2%
Q2 24	—	+21.9%
Q3 24	—	+112.4%
Q4 24	—	+28.6%
Q1 25	—	+14.3%
Q2 25	—	+8.4%
Q3 25	—	-17.0%
Q4 25	—	+80.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$0	—
Q3 23	$0	—
Q4 23	$0	—
Q1 24	$0	—
Q2 24	$0	—
Q3 24	$0	—
Q4 24	$0	—
Q1 25	$0	—
Q2 25	$0	—
Q3 25	$0	—
Q4 25	$4M	—

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$3M	$1M
Q2 22	$4M	$1M
Q3 22	$2M	$1M
Q4 22	$4M	$1M
Q1 23	$2M	$1M
Q2 23	$1M	$2M
Q3 23	$608.0K	$2M
Q4 23	$2M	$2M
Q1 24	$2M	$1M
Q2 24	$3M	$2M
Q3 24	$3M	$2M
Q4 24	$3M	$2M
Q1 25	$2M	$2M
Q2 25	$2M	$3M
Q3 25	$3M	$1M
Q4 25	$5M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$10M	$0	$10M
Q2 22	$9M	$0	$9M
Q3 22	$20M	$0	$20M
Q4 22	$17M	$0	$17M
Q1 23	$13M	$0	$13M
Q2 23	$12M	$0	$12M
Q3 23	$11M	$0	$11M
Q4 23	$9M	$0	$9M
Q1 24	$22M	$0	$22M
Q2 24	$19M	$0	$19M
Q3 24	$16M	$0	$16M
Q4 24	$12M	$67.6K	$12M
Q1 25	$10M	$56.9K	$10M
Q2 25	$12M	$42.4K	$12M
Q3 25	$8M	$23.9K	$8M
Q4 25	$16M	$0	$16M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	46M	+0.3%	+30.4%
Q2 22	47M	+2.3%	+25.6%
Q3 22	58M	+23.0%	+44.9%
Q4 22	59M	+1.1%	+27.6%
Q1 23	59M	+0.3%	+27.5%
Q2 23	59M	+0.4%	+25.2%
Q3 23	59M	+0.3%	+2.2%
Q4 23	60M	+0.3%	+1.4%
Q1 24	60M	+1.0%	+2.1%
Q2 24	70M	+16.2%	+18.1%
Q3 24	70M	+0.2%	+17.9%
Q4 24	70M	+0.4%	+18.0%
Q1 25	71M	+0.5%	+17.4%
Q2 25	72M	+1.8%	+2.9%
Q3 25	73M	+1.7%	+4.4%
Q4 25	72M	-1.1%	+2.8%

Shares Outstanding